NCT01451333View on ClinicalTrials.gov

The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1

PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

February 28, 2013

Conditions
HIV Infection
Interventions
DRUG

Efavirenz

600mg qd; 3 x 200mg qd

DRUG

Efavirenz

400mg qd; 2 x 200mg

Trial Locations (5)

10330

HIVNAT Research Collaboration, Patumwan

10777

Medical Group Practice, Berlin

40002

Khon Kaen University, Khon Kaen

W2 1NY

Imperial College, St. Mary's Hospital, Clinical Trials Centre, Winston Churchil Wing

SW10 9NH

Chelsea and Westminster Hospital, Hiv/gum Laboratory 5th Floor Saint Stephen Centre

Sponsors

Lead Sponsor

Kirby Institute
All Listed Sponsors
collaborator

Imperial College London

OTHER

lead

Kirby Institute

OTHER_GOV